Hybrid Closed Loop Therapy And Verapamil For Beta Cell Preservation In New Onset Type 1 Diabetes (Clver): Extension Study
AN
Anna Neyman
Principal Investigator
Status: Recruiting
Ages: 7 Years - 18 Years
Gender: All Genders
Phase: N/A
3 Locations
Brief Description
The aim of this study is to learn more about the long-term effectiveness of hybrid closed-loop system and verapamil in treating type 1 diabetes.
Detailed Description
Participants who have participated in the first CLVer trial are eligible to join the extended CLVer trial. Researchers will contact participants every three months and ask about continuous glucose monitoring data and health history. Researchers will invite participants to a yearly in-person visit. Participants will be enrolled in this study for three years.
Eligibility of study
Inclusion Criteria:
- Has participated in the previous CLVer trial
- Able and willing to provide informed consent
Exclusion Criteria:
- Unable or unwilling to provide informed consent